Conflict of interest: A.O. has received grants from Sanofi and consultancy or speaker fees or travel support from Advicciene, Astellas, Astrazeneca, Amicus, Amgen, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Menarini, Mundipharma, Kyowa Kirin, Alexion, Freeline, Idorsia, Chiesi, Otsuka, Novo-Nordisk and Vifor Fresenius Medical Care Renal Pharma and is Director of the Catedra Mundipharma-UAM of diabetic kidney disease and the Catedra Astrazeneca-UAM of chronic kidney disease and electrolytes. CJF has received speaker fees from Pfizer and Bayer. P.S. has received Consultant fees from Innovis Pharma, Bayer, Primeview, Healthink, Recor Medical and Boehringer Ingelheim and Speaker Fees from Winmedica, Boehringer Ingelheim, Bayer, Sanofi, AstraZeneca, Genesis Pharma, Astellas and Menarini. He has received research support from AstraZeneca, Boehringer Ingelheim, Elpen Pharmaceuticals and Servier. He has received travel/accommodation support from Winmedica, Genesis Pharma and Elpen Pharmaceuticals. He is a Council Member of European Renal Association.